

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

SUSPENSION OF TRADING

Reference is made to the announcement (the “**Announcement**”) and supplemental announcement published by Sunho Biologics, Inc. (the “**Company**”) dated March 27, 2026 and March 30, 2026, respectively, in relation to (1) the delay in publication of the 2025 Annual Results; (2) postponement of Board Meeting; and (3) possible suspension of trading. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

At the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on April 1, 2026 until the publication of the announcement in relation to the 2025 Annual Results by the Company.

By order of the Board
Sunho Biologics, Inc.

Mr. ZHANG Feng

Chairman and executive Director

Hong Kong, April 1, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.